Abstract:Qiuning Wang, 1, &ast Weiying Chen, 2, &ast Xuefeng Yang, 3 Ying Song, 4 Xiaowei Sun, 5 Guizhou Tao, 6 Hong Wang, 7 Nan Zhao, 7 Yue Huang, 1 Erqing Chai, 8 Futian Tang 9 1 Department of Pharmacology, Jinzhou Medical University, Jinzhou, Liaoning Province, People's Republic of China; 2 Department of Drug Quality Analysis, Jiuquan Drug Inspection and Testing Center, Jiuquan, Gansu Province, People's Republic of China; 3 Department of Physiology, Jinzhou Medical University, Jinzhou, Liaoning Province, People's Republic of China; 4 Cardiovascular Laboratory, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning Province, People's Republic of China; 5 Department of Neurosurgery, China Resources Liaojian Group, General Hospital of Fuxin Mining Group (10th Clinical College of China Medical University), Fuxin, Liaoning Province, People's Republic of China; 6 Internal Medicine-Cardiovascular Department, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning Province, People's Republic of China; 7 Allergy and Clinical Immunology Center, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning Province, People's Republic of China; 8 Neurointerventional Department, Emergency General Hospital, Beijing, People's Republic of China; 9 Department of Cardiovascular Disease and Key Laboratory of Digestive System Tumor of Gansu Province, Lanzhou University Second Hospital, Lanzhou, Gansu Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Futian Tang, Department of Cardiovascular Disease and Key Laboratory of Digestive System Tumor of Gansu Province, Lanzhou University Second Hospital, Lanzhou, Gansu Province, People's Republic of China, Email Erqing Chai, Neurointerventional Department, Emergency General Hospital, Beijing, People's Republic of China, Email Introduction: Astragaloside IV (AS-IV) is one of the main active components isolated from the traditional Chinese medicinal herb, Astragalus membranaceus . The present study was designed to investigate whether the regulation of microRNA-1 (miR-1)-mediated inflammation and autophagy contributes to the protective effect of AS-IV against cardiac dysfunction in rats treated with lipopolysaccharides (LPS). Methods: Animal model of cardiac dysfunction in rats or cellular model of injured H9c2 heart cell line was established by using LPS. Echocardiography, electron microscopy, enzyme-linked immunosorbent assay, immunofluorescence, quantitative RT-PCR, and Western blotting were used to determine the cardiac function and expression of inflammation- and autophagy-related proteins at both the mRNA and protein levels. Results: LPS caused cardiac dysfunction in rats or injury in H9c2 cells and induced inflammation and autophagy. Compared with LPS treatment, AS-IV treatment attenuated cardiac dysfunction or cell injury, accompanied by inhibition of inflammation and autophagy. However, the miR-1 mimics partly abolished the effects of AS-IV. In addition, the effect of the miR-1 inhibitor was similar to that of AS-IV in the LPS model. Further analyses showed that AS-IV treatment decreased the mRNA expression of miR-1 in the heart tissue of rats and H9c2 cells treated with LPS. Conclusion: These results suggest that AS-IV attenuated cardiac dysfunction caused by LPS by inhibiting miR-1-mediated inflammation and autophagy, thereby providing a novel mechanism for the protection against cardiac diseases. Keywords: lipopolysaccharides, astragaloside IV, cardiac dysfunction, inflammation, autophagy, miRNA-1 Astragali Radix is prepared from the roots of Astragalus membranaceus (Fisch.) Bunge. 1 As a kind of traditional Chinese medicine, Astragali Radix has a wide range of pharmacological effects, especially on cardiovascular diseases, such as coronary heart disease, 2 heart failure, 3 viral myocarditis, 4 and hypertension. 5 Astragaloside IV (AS-IV), one of the main active ingredients in A. membranaceus , exerts various protective effects against cardiovascular diseases, such as preventing the endothelial dysfunction of the aortas in streptozotocin-induced diabetic mice, 6 ameliorating lead-related cognitive impairments in mice, 7 attenuating hypoxia-induced pulmonary vascular remodeling, 8 and restoring myocardial infarction-induced cardiac dysfunction. 9 Many studies have shown that several mechanisms contribute to the protective effects -Abstract Truncated-

Astragaloside IV Inhibits Cardiac Fibrosis Via Mir-135A-trpm7-tgf-β/smads Pathway.

AstragalosideⅣ against cardiac fibrosis by inhibiting TRPM7 channel

The role of astragaloside IV in extracellular matrix remodeling in fibrotic heart disease: Regulation of TRPM7-dependent macrophage function

Astragalus membranaceus extract promotes neovascularisation by VEGF pathway in rat model of ischemic injury.

Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway

Inhibition of miRNA-1-Mediated Inflammation and Autophagy by Astragaloside IV Improves Lipopolysaccharide-Induced Cardiac Dysfunction in Rats

Astragaloside IV Ameliorates Isoprenaline-Induced Cardiac Fibrosis in Mice via Modulating Gut Microbiota and Fecal Metabolites

Astragaloside IV-targeting miRNA-1 attenuates lipopolysaccharide-induced cardiac dysfunction in rats through inhibition of apoptosis and autophagy

Preventive Effects of Astragaloside IV and Its Active Sapogenin Cycloastragenol on Cardiac Fibrosis of Mice by Inhibiting the NLRP3 Inflammasome.

Astragalus propinquus schischkin and Salvia miltiorrhiza bunge promote angiogenesis to treat myocardial ischemia via Ang-1/Tie-2/FAK pathway

Astragaloside IV inhibits angiotensin II-induced atrial fibrosis and atrial fibrillation by SIRT1/PGC-1α/FNDC5 pathway

Astragalus Saponin Attenuates the Expression of Fibrosis-Related Molecules in Irradiated Cardiac Fibroblasts

Astragaloside IV alleviates LPS-induced cardiomyocyte hypertrophy and collagen expression associated with CCL2-mediated activation of NF-κB signaling pathway

Integrative transcriptomics and proteomics analysis reveal the protection of Astragaloside IV against myocardial fibrosis by regulating senescence

Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases

Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling

Extracts from Astragalus Membranaceus Limit Myocardial Cell Death and Improve Cardiac Function in a Rat Model of Myocardial Ischemia.

Chinese Medicinal Herb Radix Astragali Suppresses Cardiac Contractile Dysfunction and Inflammation in a Rat Model of Autoimmune Myocarditis

Astragaloside IV Attenuates Myocardial Fibrosis by Inhibiting TGF-β1 Signaling in Coxsackievirus B3-induced Cardiomyopathy

Astragaloside IV promotes cardiac remodeling after myocardial infarction by inhibiting DNMT3B-mediated Runx3 methylation via downregulating LncRNA MIRT1 expression

Astragaloside Iv Suppresses Transforming Growth Factor-Beta 1 Induced Fibrosis Of Cultured Mouse Renal Fibroblasts Via Inhibition Of The Mapk And Nf-Kappa B Signaling Pathways